Skip to main content
. 2013 Aug 12;6(19):17314–17327. doi: 10.18632/oncotarget.1168

Figure 3. CHR-3996 overcomes the protective effect of the bone marrow microenvironment.

Figure 3

Bone marrow stromal cells were cultured from bone marrow aspirates obtained from three patients with myeloma. A. The bone marrow stromal cells were treated with a range of CHR-3996 concentrations for 24 hours. The number of viable cells was measured by metabolic activity (WST-1 assay) and is shown as a percentage of untreated cells. B. H929 (i) or RPMI-8226 (ii) cells were treated with CHR-3996 in the presence or absence of the bone marrow stromal cells (performed in triplicate) for 24 hours. The proliferation of the cells was monitored by metabolic activity (WST-1 assay) and is shown as a percentage of untreated cells. IL-6 C. and VEGF D. secreted by the bone marrow stromal cells over 24 hours in isolation or in a co-culture with H929 or RMPI-8226 cells and with or without CHR-3996 treatment were measured by ELISA. The data was compared using a one-tailed paired Student's T Test and ** indicates a p value of <0.05.